Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System

We aimed to evaluate and compare the performance of multiple myeloma (MM) selection algorithms for use in Veterans Affairs (VA) research.

[1]  N. Munshi,et al.  Contemporary Analysis of Electronic Frailty Measurement in Older Adults with Multiple Myeloma Treated in the National US Veterans Affairs Healthcare System , 2021, Cancers.

[2]  Shaji K. Kumar,et al.  Paving the way to precision medicine in multiple myeloma , 2021, Expert review of hematology.

[3]  Sheila Ochylski,et al.  Big Data in the Veterans Health Administration: A Nursing Informatics Perspective. , 2021, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.

[4]  G. Abel,et al.  Defining multimorbidity and its impact in older united states veterans newly treated for multiple myeloma. , 2021, Journal of the National Cancer Institute.

[5]  H. Krumholz,et al.  Prevalence of Missing Data in the National Cancer Database and Association With Overall Survival , 2020, JAMA network open.

[6]  S. Rajkumar,et al.  Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management , 2020, American journal of hematology.

[7]  N. Aggarwal.  Ramifications of the VA MISSION Act of 2018 on Mental Health: Potential Implementation Challenges and Solutions. , 2019, JAMA psychiatry.

[8]  B. Gage,et al.  Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score , 2019, American journal of hematology.

[9]  G. Abel,et al.  Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma. , 2019, Journal of Clinical Oncology.

[10]  A. Figueiras,et al.  Bias in pharmacoepidemiologic studies using secondary health care databases: a scoping review , 2019, BMC Medical Research Methodology.

[11]  S. Oliveria,et al.  Validating an algorithm for multiple myeloma based on administrative data using a SEER tumor registry and medical record review , 2019, Pharmacoepidemiology and drug safety.

[12]  M. Dimopoulos,et al.  Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting , 2018, Blood Cancer Journal.

[13]  R. Vij,et al.  Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets. , 2017, JCO clinical cancer informatics.

[14]  Robert Platt,et al.  Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. , 2016, Journal of clinical epidemiology.

[15]  S. Rajkumar,et al.  Daratumumab in multiple myeloma , 2016, The Lancet.

[16]  K. Shea,et al.  The Veterans Affairs's Corporate Data Warehouse: Uses and Implications for Nursing Research and Practice , 2015, Nursing administration quarterly.

[17]  Medicaid Services.  Strategies and Priorities for Information Technology at the Centers for Medicare and Medicaid Services , 2011 .

[18]  R. Kyle,et al.  Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). , 2011, Oncology.

[19]  R. Kyle,et al.  From Myeloma Precursor Disease to Multiple Myeloma: New Diagnostic Concepts and Opportunities for Early Intervention , 2011, Clinical Cancer Research.

[20]  Jasvinder A Singh,et al.  Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis. , 2004, Arthritis and rheumatism.

[21]  M. Kelley,et al.  Summary of Veterans Health Administration Cancer Data Sources. , 2019, Journal of registry management.

[22]  Processes,et al.  COMMITTEE ON FUTURE INFORMATION ARCHITECTURES, PROCESSES, AND STRATEGIES FOR THE CENTERS FOR MEDICARE AND MEDICAID SERVICES , 2010 .